DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth

Molecular Pharmacology

Volumn 82, Issue 2, 2012, Pages 189-198

  Deng, Rong ^a   Yang, Fen ^a   Chang, Shao Hua ^c,d   Tang, Jun ^a,b   Qin, Juan ^a   Feng, Gong Kan ^a   Ding, Ke ^c,d   Zhu, Xiao Feng ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CASPASE 3; DC 120; GLYCOGEN SYNTHASE KINASE 3BETA; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; N [1 AMINO 3 (2,4 DICHLOROPHENYL)PROPAN 2 YL] 2 [2 (METHYLAMINO)PYRIMIDIN 4 YL]THIAZOLE 5 CARBOXAMIDE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE INHIBITOR; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; UO 126;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CANCER INHIBITION; CELL ASSAY; CELL CYCLE G1 PHASE; CELL NUCLEUS; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR XENOGRAFT; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; SIGNAL TRANSDUCTION; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863884205     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.077271     Document Type: Article

References (40)

1. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, and Testa JR (2004) Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25:2053-2059.
2. Bellacosa A, Kumar CC, Di Cristofano A, and Testa JR (2005) Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 94:29-86.
3. Caporali S, Levati L, Starace G, Ragone G, Bonmassar E, Alvino E, and D'Atri S (2008) AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 74:173-183.
4. Chakrabarty A, Sánchez V, Kuba MG, Rinehart C, and Arteaga CL (2012) Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. Proc Natl Acad Sci USA 109:2718-2723.
5. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, Majumder PK, Baselga J, and Rosen N (2011) AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19:58-71.
6. Chang S, Zhang Z, Zhuang X, Luo J, Cao X, Li H, Tu Z, Lu X, Ren X, and Ding K (2012) New thiazole carboxamides as potent inhibitors of Akt kinases. Bioorg Med Chem Lett 22:1208-1212.
7. Crowell JA, Steele VE, and Fay JR (2007) Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 6:2139-2148.
8. Deng R, Tang J, Ma JG, Chen SP, Xia LP, Zhou WJ, Li DD, Feng GK, Zeng YX, and Zhu XF (2011) PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene 30:944-955.
9. Deng R, Tang J, Xia LP, Li DD, Zhou WJ, Wang LL, Feng GK, Zeng YX, Gao YH, and Zhu XF (2009) ExcisaninA, a diterpenoid compound purified from Isodon MacrocalyxinD, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther 8:873-882.
10. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562.
11. Hers I, Vincent EE, and Tavaré JM (2011) Akt signalling in health and disease. Cell Signal 23:1515-1527.
12. Hirai H, Sootome H, Nakatsuru Y, Miyama K, Taguchi S, Tsujioka K, Ueno Y, Hatch H, Majumder PK, Pan BS, et al. (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9:1956-1967.
13. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
14. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, Natesan S, and Brugge JS (2005) Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 171:1023-1034.
15. Janku F, McConkey DJ, Hong DS, and Kurzrock R (2011) Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 8:528-539.
16. Kalinsky K, Heguy A, Bhanot UK, Patil S, and Moynahan ME (2011) PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression. Breast Cancer Res Treat 129:635-643.
17. Lin X, Murray JM, Rico AC, Wang MX, Chu DT, Zhou Y, Del Rosario M, Kaufman S, Ma S, Fang E, et al. (2006) Discovery of 2-pyrimidyl-5- amidothiophenes as potent inhibitors for AKT: synthesis and SAR studies. Bioorg Med Chem Lett 16:4163-4168.
18. V600E inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab 97:E173-E182.
19. LoPiccolo J, Granville CA, Gills JJ, and Dennis PA (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18:861-874.
20. Luo Y, Shoemaker AR, Liu X, Woods KW, Thomas SA, de Jong R, Han EK, Li T, Stoll VS, Powlas JA, et al. (2005) Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo. Mol Cancer Ther 4:977-986.
21. Manning BD and Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274.
22. 3 receptors. Mol Pharmacol 79:91-105.
23. Markaryan A, Nelson EG, Tretiakova M, and Hinojosa R (2008) Technical report: immunofluorescence and TUNEL staining of celloidin embedded human temporal bone tissues. Hear Res 241:1-6.
24. McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M, et al. (2010) Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem 53:2239-2249.
25. Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, Peng Z, Herbst RS, Papadimitrakopoulou V, Minna JD, et al. (2010) Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One 5:e14124.
26. Nakanishi T and Ross DD (2012) Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer 31:73-99.
27. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, and Shokat KM (2009) Inhibitor hijacking of Akt activation. Nat Chem Biol 5:484-493.
28. Rhodes N, Heerding DA, Duckett DR, Eberwein DJ, Knick VB, Lansing TJ, McConnell RT, Gilmer TM, Zhang SY, Robell K, et al. (2008) Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68:2366-2374.
29. Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, et al. (2011) Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 29:4243-4249.
30. Seefeld MA, Rouse MB, McNulty KC, Sun L, Wang J, Yamashita DS, Luengo JI, Zhang S, Minthorn EA, Concha NO, et al. (2009) Discovery of 5-pyrrolopyridinyl-2-thiophenecarboxamides as potent AKT kinase inhibitors. Bioorg Med Chem Lett 19:2244-2248.
31. Sun H, Yu T, and Li J (2011) Co-administration of perifosine with paclitaxel synergistically induces apoptosis in ovarian cancer cells: more than just AKT inhibition. Cancer Lett 310:118-128.
32. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, and Maehara Y (2008) Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8:27-36.
33. United Kingdom Co-ordinating Committee on Cancer Research (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (second edition). Br J Cancer 77:1-10.
34. Wei L and Xu Z (2011) Cross-signaling among phosphinositide-3 kinase, mitogen-activated protein kinase and sonic hedgehog pathways exists in esophageal cancer. Int J Cancer 129:275-284.
35. Whitehall VL, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A, McKeone D, Faleiro RJ, Buttenshaw RL, Worthley DL, et al. (2011) Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer. http://dx.doi.org/10.1002/ijc.26440.
36. Wu JB and Shih JC (2011) Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol Pharmacol 80:714-723.
37. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia SV, Herlyn M, et al. (2004) Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res 64:4394-4399.
38. Zhang CH, Wen ZQ, Li JF, Li CZ, Shi M, Yang GW, Lan SM, Zhu Y, Wang F, Zhang YJ, et al. (2008) Inhibition of proliferation and transforming growth factor β3 protein expression by peroxisome proliferators-activated receptor γ ligands in human uterine leiomyoma cells. Chin Med J (Engl) 121:166-171.
39. Zhou WJ, Deng R, Zhang XY, Feng GK, Gu LQ, and Zhu XF (2009) G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther 8:3203-3213.
40. Zhu GD, Gandhi VB, Gong J, Thomas S, Woods KW, Song X, Li T, Diebold RB, Luo Y, Liu X, et al. (2007) Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension. J Med Chem 50:2990-3003.